Inventor · disambiguated record
Yasumichi Hitoshi
Also filed as: HITOSHI YASUMICHI
21 granted patents·19 pending applications·175 citations·filing 1998–2022
95Inventor score
Files withRIGEL PHARMACEUTICALS INC26THYAS CO LTD5HITOSHI YASUMICHI2RIGEL PHARMACEUTICALS2GOFF DANE1
Top patents by PatentIndex Score
40 records- 0197US10941134B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2019·Granted Mar 9, 2021·18 cites·20 claims
- 0297US10377742B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2017·Granted Aug 13, 2019·20 cites·21 claims
- 0395US8809370B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Aug 19, 2014·17 cites·7 claims
- 0495US8791136B2Substituted pyridine, pyridazine, pyrazine and pyrimidine compounds and methods for using the sameGOFF DANE·Filed 2011·Granted Jul 29, 2014·26 cites·27 claims
- 0594US8987303B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Mar 24, 2015·16 cites·24 claims
- 0694US8980921B2AMPK-activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2013·Granted Mar 17, 2015·16 cites·7 claims
- 0793US9266856B2AMPK—activating heterocyclic compounds and methods for using the sameRIGEL PHARMACEUTICALS INC·Filed 2014·Granted Feb 23, 2016·14 cites·30 claims
- 0888US8546433B2Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancerHITOSHI YASUMICHI·Filed 2010·Granted Oct 1, 2013·12 cites·10 claims
- 0977US7056687B2Methods and compositions for screening for altered cellular phenotypesRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Jun 6, 2006·4 cites·59 claims
- 1075US9005909B2Whole blood assay for measuring AMPK activationMARKOVTSOV VADIM·Filed 2011·Granted Apr 14, 2015·3 cites·16 claims
- 1175US2021379064A1Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancerRIGEL PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1268US8796254B2Methods for using carboxamide, sulfonamide and amine compoundsPAYAN DONALD·Filed 2011·Granted Aug 5, 2014·2 cites·21 claims
- 1367US6727350B2TosoUNIV LELAND STANFORD JUNIOR·Filed 1998·Granted Apr 27, 2004·15 cites·3 claims
- 1466US7005254B2LETM1: modulators of cellular proliferationRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Feb 28, 2006·8 cites·29 claims
- 1565US2022098175A1Direct ampk activatorsRIGEL PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1665US2019336500A1Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancerRIGEL PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1761US2009012045A1Methods of Treating Cell Proliferative DisordersRIGEL PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 1861US2013338161A1Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancerRIGEL PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1960US2023183645A1Method for producing regenerated t cells via ips cellsTHYAS CO LTD·Filed 2021·Application pending·0 cites
- 2059US2024052309A1Method for producing regenerated t cell via ips cellTHYAS CO LTD·Filed 2021·Application pending·0 cites
- 2159US2025177524A1Cell bank composed of ips cells for introducing t cell receptor geneTHYAS CO LTD·Filed 2022·Application pending·0 cites
- 2257US2017042891A1Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancerRIGEL PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2356US9383362B2Whole blood assay for measuring AMPK activationRIGEL PHARMACEUTICALS INC·Filed 2015·Granted Jul 5, 2016·0 cites·22 claims
- 2456US7413870B2SAK: modulation of cellular proliferation for treatment of cancerRIGEL PHARMACEUTICALS INC·Filed 2001·Granted Aug 19, 2008·2 cites·9 claims
- 2556US7090990B2NP95: methods of assaying for cell cycle modulatorsRIGEL PHARMACEUTICALS INC·Filed 2002·Granted Aug 15, 2006·2 cites·25 claims
- 2655US9511058B2Methods for using carboxamide, sulfonamide and amine compoundsRIGEL PHARMACEUTICALS INC·Filed 2014·Granted Dec 6, 2016·0 cites·25 claims
- 2752US7863222B2shRNA libraryRIGEL PHARMACEUTICALS INC·Filed 2008·Granted Jan 4, 2011·0 cites·7 claims
- 2852US2006216299A1Cell cycle targets and peptidesRIGEL PHARMACEUTICALS INC·Filed 2003·Application pending·0 cites
- 2951US7482130B2NP95: methods of assaying for cell cycle modulatorsRIGEL PHARMACEUTICALS INC·Filed 2006·Granted Jan 27, 2009·0 cites·13 claims
- 3050US11174246B2Direct AMPK activatorsRIGEL PHARMACEUTICALS INC·Filed 2017·Granted Nov 16, 2021·0 cites·33 claims
- 3150US2006147978A1Methods and compositions for screening for altered cellular phenotypesLORENS JAMES·Filed 2006·Application pending·0 cites
- 3250US2022233665A1Medicinal compositionTHYAS CO LTD·Filed 2020·Application pending·0 cites
- 3348US2015087673A1Methods for using and biomarkers for ampk-activating compoundsHITOSHI YASUMICHI·Filed 2014·Application pending·0 cites
- 3448US2009048214A1Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug CompoundsRIGEL PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 3547US2021238550A1METHOD FOR PRODUCING REGENERATED T CELL POPULATION VIA iPS CELLSTHYAS CO LTD·Filed 2019·Application pending·0 cites
- 3642US2004126784A1Modulators of cellular proliferationRIGEL PHARMACEUTICALS INC·Filed 2003·Application pending·0 cites
- 3742US2018296579A1Methods of treating ibrutinib-resistant diseaseRIGEL PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3841US7358040B2MRE 11: modulation of cellular proliferationRIGEL PHARMACEUTICALS INC·Filed 2001·Granted Apr 15, 2008·0 cites·22 claims
- 3938US2006051755A1Methods of assaying for cell cycle modulatorsRIGEL PHARMACEUTICALS·Filed 2003·Application pending·0 cites
- 4036US2003195138A1BAP-1: methods of assaying for cell-cycle modulatorsRIGEL PHARMACEUTICALS·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yasumichi Hitoshi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →